Granulosa cell tumors of the ovary represent B5% of malignant ovarian cancers. It has recently been reported that 95-97% of adult granulosa cell tumors carry a unique somatic mutation in the FOXL2 gene. We undertook this study to verify the presence of the FOXL2 Cys134Trp mutation in two geographically independent cohorts of granulosa cell tumors and to examine the expression pattern of FOXL2 in these tumors. A total of 56 tumors with the histological diagnosis of adult granulosa cell tumor from two centers, Melbourne and Helsinki, were examined for the presence of the mutation using direct sequence analysis. Two granulosa cell tumor-derived cell lines, COV434 and KGN, three juvenile granulosa cell tumors and control tissues were also examined. The expression of the FOXL2 gene was determined using quantitative RT-PCR and/or immunohistochemistry. We found that 52 of the 56 adult granulosa cell tumors harbor the mutation, of which three were hemi/homozygous. Of the four cases with wild-type FOXL2 sequence, reappraisal suggests that three may have been misclassified at primary diagnosis. The KGN cells were heterozygous for the mutation, whereas the COV434 cells had a wildtype FOXL2 genotype. The expression levels of FOXL2 were similar across the adult granulosa cell tumors and the normal ovary controls; one mutation-negative granulosa cell tumor had high FOXL2 mRNA levels, whereas the COV434 cells and two of the three juvenile granulosa cell tumors lacked the expression of FOXL2. Our data provide confirmation of the frequent presence of the FOXL2 C134W mutation in adult granulosa cell tumors and demonstrate that the mutation is not associated with altered FOXL2 expression. The mutation analysis may be a useful tool to differentiate particularly between cell-rich diffuse granulosa cell tumors and mitotically active sex cord-stromal tumors. This unique FOXL2 mutation appears to be characteristic of adult granulosa cell tumors.
Granulosa cell tumors of the ovary represent B5% of malignant ovarian cancers. 1, 2 Two distinct subtypes have been described based on clinical presentation and histological characteristics: the juvenile and the adult form. The adult form accounts for 95% of granulosa cell tumors and most commonly presents during the perimenopausal or early postmenopausal period. 3 Granulosa cell tumors are characterized by slow, indolent growth and a tendency to late recurrence, with intervals in excess of 10 or 20 years not being uncommon. Although the prognosis is often favorable, those that recur and/or are at an advanced stage carry a poor prognosis with B80% of these patients succumbing to their disease. 3 Although granulosa cell tumors seem to represent a relatively homogenous group of tumors, a molecular etiology has until recently eluded investigators. 4 The molecular changes that give rise to granulosa cell tumors are likely to involve disruption of pathways that function during normal ovarian development to regulate granulosa cell proliferation. Indeed, granulosa cell tumors exhibit a gene expression profile consistent with that of normal proliferating granulosa cells of preantral follicles. [5] [6] [7] A range of these genes, as well as genes commonly mutated in human malignancy, have been examined for mutations and/or altered expression in granulosa cell tumors without success. 4 This situation abruptly changed in 2009 with the report of a somatic mutation in the FOXL2 gene (C402G; Cys134Trp) that was present in 97% of adult granulosa cell tumors. 8 The mutation was found in only one juvenile granulosa cell tumor 8 and not found in a wide range of other tumors, both gonadal and non-gonadal. 9, 10 Curiously, diminished and/or loss of FOXL2 expression has been reported in advanced stage/aggressive juvenile granulosa cell tumors. 11 In this study, we sought to confirm the presence of this mutation in two geographically independent cohorts of granulosa cell tumors and to examine the expression pattern of the FOXL2 gene in these tumors.
Materials and methods

Melbourne
Human tissue samples Ovarian granulosa cell tumors and normal ovarian tissue were obtained initially for a study of serum inhibin levels in ovarian tumors 12, 13 and subsequently for studies of the molecular pathogenesis of granulosa cell tumors. 5, [14] [15] [16] [17] [18] [19] Normal ovarian tissue was obtained from premenopausal women who had undergone elective hysterectomy with oophorectomy for a range of conditions not associated with ovarian malignancy (Supplementary Table 1) . RNA from the tissue and the two granulosa cell tumorderived cell lines was extracted using the guanidine thiocyanate/cesium chloride method as described previously.
14 Tissue collection was approved by the research and ethics committee of the Monash Medical Centre, and all women gave written informed consent before tissue collection.
Cell lines
The two human granulosa cell tumor-derived cell lines, COV434 and KGN, have been previously described. 20 COV434 cells were maintained in DMEM and KGN cells in DMEM/F12 both supplemented with 10% FCS at 37 1C in a 95% air/5% CO 2 humidified incubator.
Mutation analysis
Total RNA (1 mg) was reverse-transcribed for 60 min at 50 1C in a total volume of 20 ml using SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). First-strand synthesis was performed using 250 ng random hexamers. The oligonucleotide primers (sense 5 0 -CACAACCTCAACGAGTGC-3 0 , antisense 5 0 -TTGCCGGGCTGGAAGTGCG-3 0 ) and PCR conditions used to amplify FOXL2 were those of Shah et al, 8 using a Veriti TM 96-well Thermal Cycler (Applied Biosystems, Foster City, CA, USA). In all cases, an amplicon of the predicted size (182 bp) when compared with the molecular weight standards was obtained. The PCR products were purified using a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). For each sample, forward and reverse sequences were determined using the primers described above as sequencing primers and a BigDyes Terminator Cycle Sequencing Ready Reaction Kit, v3.1 (Applied Biosystems), according to the manufacturer's protocol. The analysis was carried out using ABI 3130xl Genetic Analyzer (Applied Biosystems) and assembled using Sequencher 3. 0 ) and reverse (described above) sequencing primers. Sequencing was performed at the Molecular Medicine Sequencing Laboratory, Biomedicum Helsinki, with an ABI 3730xl DNA Analyzer (Applied Biosystems) and assembled using Sequencher 4.9 software.
Quantitative PCR analysis RNA was extracted from frozen tissue samples using a NucleoSpin RNA/Protein kit (Machrey Nagel) according to the manufacturer's instructions. RNA was treated with Dnase I for 10 min at 37 1C and a NucleoSpin RNA Clean-Up kit (Machrey Nagel). In all, 800 ng of RNA was reverse transcribed using TaqMan reverse transcription reagents (Applied Biosystems, Branchburg, NJ, USA) and MultiScribe enzyme in 40 ml volume. Quantitative PCR samples were prepared to a final volume of 20 ml using Applied Biosystems SYBR Green PCR master mix, and the oligonucleotide primers for FOXL2 used were 
Results
FOXL2 C143W Mutation Status
Employing direct sequence analysis, we examined our tumor panels for the presence of the previously reported FOXL2 C134W mutation using RNA (Melbourne) and DNA (Helsinki) extracted from frozen tissue. Collectively, 52 of 56 adult granulosa cell tumors were found to harbor the mutation (Table 1) .
Of the mutation-positive samples, three were hemi/ homozygous, whereas the remainder were heterozygous. Peaks of equivalent height were observed on the sequence chromatograms from the heterozygous tumors, indicating equal expression of mutant to wild-type allele where RNA was analyzed. Four tumors diagnosed as adult granulosa cell tumors were null for the mutation (Table 2 ). In addition, all three juvenile granulosa cell tumors, three ovarian carcinomas and 11 whole normal ovaries were mutation negative. Of the two granulosa cell tumor-derived cell lines examined, the mutation was present in the KGN cell line, as previously reported, 9,10 but was absent in the COV434 cell line.
Details and Evaluation of the FOXL2 Wild-Type Adult Granulosa Cell Tumor Cases
Four adult granulosa cell tumors, two from each centre, were null for the mutation (Table 2 and Figure 1 ). M18 was removed from a 71-year-old woman. The pathology report described the histology as 'consistent with a granulosa cell tumor of diffuse type (poorly differentiated, 'sarcomatoid').' The patient's pre-operative serum inhibin level was a Of the mutation-positive adult granulosa cell tumors, one primary and two recurrent tumors were hemi/homozygous for the mutation. The tumor stained strongly for a-inhibin. This was a recurrent tumor although we do not have access to the patient's previous medical history. A re-evaluation of the morphology suggests that it should perhaps be classified as a thecoma or cellular fibroma rather than diffuse granulosa cell tumor. M19 was removed from an 80-year-old woman. The initial pathology report described a 'high grade malignant tumor with features suggestive of granulosa cell tumor, juvenile form'; however, an experienced gynecologic oncology pathologist was of the opinion that this was a 'high grade malignant tumor with features suggestive of granulosa cell tumor, adult type.' The tumor sections were positive for calreticulin and a-inhibin immunohistochemistry and the tumor expressed high levels of FOXL2 (Figure 2a) . A third opinion from an experienced gynecologist pathologist confirms the initial diagnosis of a juvenile granulosa cell tumor in a postmenopausal woman. 21 H29 is a primary tumor, initially diagnosed as 'diffuse or sarcomatoid form of granulosa cell tumor with moderate mitotic activity.' The tumor was a-inhibin and FOXL2 positive (Figure 1a) . In a re-evaluation of the morphology, this tumor appears in the borderline of a diffuse granulosa cell tumor and a mitotically active cellular fibroma, and given the FOXL2 mutation result, the latter appears more likely. H36 is also a primary tumor, initially diagnosed as a differentiated granulosa cell tumor and included in the ongoing prospective granulosa cell tumor study in Helsinki, being a-inhibin positive (serum inhibin 41000; Figure 1b ). It exhibits strong nuclear positivity for FOXL2 (Figure 1b) , which is similar to the mutation-positive cases (H2 as an example; Figure 1c ). Upon re-examination, taking into account the FOXL2 data, the morphology still appears to be most typical of an adult granulosa cell tumor.
FOXL2 mRNA and Protein Expression in Granulosa Cell Tumors
FOXL2 mRNA levels were determined in the two adult granulosa cell tumor panels, juvenile granulosa cell tumors, granulosa cell tumor-derived cell lines and whole normal ovaries (Figure 2) . The expression levels of FOXL2 determined by quantitative real-time PCR were similar across both the granulosa cell tumor panels and whole normal ovaries. In the Melbourne series, 15 adult granulosa cell tumors, three juvenile granulosa cell tumors, two granulosa cell tumor-derived cell lines and 10 whole normal ovaries were examined (Figure 2a) . Although the expression levels were comparable across most adult granulosa cell tumors and normal ovary samples, high expression was observed in one of the mutation-negative adult granulosa cell tumor samples (M19). Little to no FOXL2 expression was observed in two of the three juvenile granulosa cell Table 2 Clinicopathological details of the four adult granulosa cell tumor cases null for the FOXL2 C134W mutation tumor samples (M20, M21 and M22) consistent with a previous report. 11 The COV434 cell line was found not to express FOXL2 mRNA, which was confirmed by absent immunostaining for FOXL2 (data not shown). The relative expression levels for FOXL2 were comparable across the Helsinki series of 31 adult granulosa cell tumors with no samples exhibiting significantly higher expression (Figure 2b) . Immunostaining of the 35 mutation-positive cases in Helsinki as well as the mutation-negative H36 exhibited nuclear positivity of FOXL2 in 440% of the tumors cells, whereas H29 exhibited diffuse cytoplasmic staining and only occasionally positive nuclear staining (Figure 1 and Supplementary Table 2 ). There was no correlation of clinicopathological status (stage, subtype, nuclear atypia, mitotic index, inhibin staining and nuclear FOXL2 immunoreactivity) with FOXL2 mRNA levels.
Discussion
Granulosa cell tumors of the ovary are relatively uncommon neoplasms, representing approximately 5% of all ovarian malignancies.
1,2 They are thought to arise from the granulosa cells of the ovary. 22 Granulosa cell tumors secrete gonadal peptides including inhibin and Mü llerian inhibiting substance (MIS)/anti-Mü llerian hormone (AMH), and synthesize estrogen. 4, 22 These properties together with the gene expression profiles are characteristic of proliferating preovulatory granulosa cells. [5] [6] [7] Previous studies of granulosa cell tumors have sought altered expression and/or mutations of genes expressed in normal proliferating granulosa cells, 6 including transcription factors such as GATA4, 7, 23 and genes commonly mutated in human malignancy, 4 including ras 16 and PTEN/PI3-kinase.
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Neither mutations nor robust predictors of disease have been identified, although Anttonen et al 7 have found that high GATA-4 expression, a feature of proliferating granulosa cells, is associated with advanced stage and/or a risk of recurrence in adult granulosa cell tumors.
Using whole-transcriptome paired-end RNA sequencing of four granulosa cell tumors, Shah et al 8 identified a single somatic, missense mutation in FOXL2 (C402G). This mutation predicts substitution of a tryptophan residue for a highly conserved cysteine residue at amino acid position 134 (Cys134Trp). 8 Subsequent direct sequencing of DNA from additional granulosa cell tumors revealed the mutation to be present in 86/89 (97%) of morphologically identified adult granulosa cell We examined two panels of granulosa cell tumors for the presence of the FOXL2 C134W mutation and obtained results consistent with the previous two reports, 8, 24 demonstrating a high frequency of the mutation. Of the mutation-positive cases, three were hemi/homozygous for the mutation. Shah et al 8 reported three cases in which only the mutant allele was identified; it is not clear whether this represents a double somatic mutation or loss of the wild-type allele, although the latter would seem more likely. Of the four adult granulosa cell tumors negative for the mutation, one showed high levels of FOXL2 mRNA expression, which may suggest that overexpression of FOXL2 has a role in the pathogenesis of this tumor. However, it seems more likely that rather than being a variant adult granulosa cell tumor, this is an atypical juvenile granulosa cell tumor. Two other cases would appear, on reappraisal of the morphology, most likely to represent thecomas or cellular fibromas; this is consistent with the two previous reports. 8, 24 The one FOXL2 mutation-negative tumor that remains classified as an adult granulosa cell tumor after reevaluation exhibited true FOXL2 nuclear positivity and high serum inhibin levels. The high frequency with which the mutation occurs in adult granulosa cell tumors and its virtual absence from juvenile granulosa cell tumors and other sex cord-stromal tumor types 8, 9, 24 argues that this FOXL2 mutation is the key characteristic of an adult-type granulosa cell tumor. Although a minority of thecomas have been reported to be FOXL2 mutation positive, 8, 24 these have had granulosa cell-like elements, suggesting that the distinction between these two entities should be based on both genetics and morphology. In a clinical setting, screening for the mutation is likely to be a useful diagnostic tool to differentiate the morphologically challenging tumors, particularly the diffuse adult granulosa cell tumors and the mitotically active sex-cord stromal tumors.
FOXL2 mRNA levels in adult granulosa cell tumors have not previously been examined. In this study, FOXL2 mRNA levels in the mutationpositive granulosa cell tumors were similar across the two series. Some differences were observed between tumors with respect to the number of cells expressing FOXL2, as determined by FOXL2 in adult granulosa cell tumors immunohistochemistry; however, this did not appear to associate with the stage of the disease or other clinicopathological parameters. The low FOXL2 mRNA expression observed in two of the three juvenile granulosa cell tumor cases correlates with the findings of Kalfa et al 11 who reported FOXL2 immunohistochemistry to be decreased or absent in juvenile granulosa cell tumors with an aggressive pattern of progression. The two juvenile granulosa cell tumors with low expression exhibited metastatic and recurrent behavior, respectively, whereas the grade I juvenile granulosa cell tumor showed expression levels comparable to that of the adult-type granulosa cell tumors and normal ovaries.
The presence of the mutation in the KGN cell line, which was derived from an 81-year-old woman with recurrent metastatic disease, 25 is consistent with previous analyses 9, 10 and suggests that it may be a useful tool to study adult granulosa cell tumors. We found that the COV434 cell line, established from a metastatic granulosa cell tumor removed from a 27-year-old female, 26, 27 lacked the FOXL2 mutation and did not express the FOXL2 gene. This strongly suggests that the COV434 cell line is derived from a juvenile granulosa cell tumor.
The FOXL2 gene encodes a member of the forkhead domain/winged-helix family of transcription factors and has a crucial role in ovarian development and maintenance. Patients carrying inactivating mutations in the FOXL2 gene display blepharophimosis/ptosis/epicanthus inversus syndrome (BPES), an autosomal dominant disease associated with eyelid defects and premature ovarian failure in females. 28 Conditional deletion of FOXL2 in transgenic mice results in transdifferentiation of the postnatal ovary into a testis, 29 indicating a fundamental role for FOXL2 in defining female gonadal development and function. A number of targets of FOXL2 have been identified in both pituitary 30 and gonadal cells. 31 In the ovary, these include a number of genes fundamental to granulosa cell function and the development of ovarian follicles, including growth differentiation factor 9 (GDF9), inhibin bA (INHBA) and MIS. 32 The regulation of gene expression by FOXL2 involves interactions with other transcription factors including nuclear receptors and the SMAD family of transcription factors; 33, 34 both have fundamental roles in ovarian biology.
The Cys134Trp mutation in FOXL2 may be etiologic in adult granulosa cell tumors, but the mechanism by which it contributes to the pathogenesis of this disease remains to be determined. Given that the mutation is universal in adult granulosa cell tumors, it does not, of course, provide prognostic information. The mutation lies in the 'wing 2' domain of the forkhead DNA-binding domain of the FOXL2 protein, in a residue that is highly conserved across species. It appears unlikely to compromise DNA binding but may influence the interaction with other transcription factors. 8 The mutant might be postulated to be either an activating mutation or a gain-of-function mutation. In an initial in vitro assay, Benayoun et al 10 found limited evidence to support activation. Given the high homology with other members of the FOX family, several of which also have fundamental roles in ovarian function, such as FOXO3a, 35 a gain of function is a distinct possibility. Benayoun et al 36 have argued that FOXL2 is a tumor-suppressor gene based on their findings in juvenile granulosa cell tumors. 11 Considering that decreased FOXL2 expression is a feature of advanced disease in juvenile GCT, 11 and therefore not etiologic, it may be a 'bystander' rather than a 'driver.' 37 With the exception of four cases, we found no evidence of loss of the wild-type FOXL2 allele in the adult granulosa cell tumors as would be expected for a tumorsuppressor gene. The presence of a single, specific mutation would seem rather more analogous to the situation seen for other oncogenic or pro-proliferative mutations.
The finding of the FOXL2 C134W mutation as an almost universal feature of adult granulosa cell tumors, 8, 24 which we have confirmed in this study from two centers, is an exciting advance in clinical molecular oncology, but many questions remain to be resolved. At a molecular level, the consequence of the mutation remains to be determined. This information may be important if tailored therapeutics are to be developed for granulosa cell tumors, as they have been for other uncommon malignancies where a single molecular mechanism has been identified. The frequency with which the FOXL2 mutation occurs in adult granulosa cell tumors suggests that it is a potential therapeutic target. However, specificity to FOXL2 and/or the mutant form may be difficult given the large number (B100) of highly homologous members of the FOX family of transcription factors. Screening for this novel mutation will be key to separating ovarian stromal tumors that will benefit from the putative tailored therapy, in addition to being a tool in the differential diagnostics of sex cord-stromal tumors. The major clinical challenge in the management of adult granulosa cell tumors remains in the treatment of recurrent or advanced disease for which prognostic markers and novel therapeutic targets are needed. 
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